AfterPay’s brave new world

Marc Kennis Marc Kennis, October 25, 2020

25 October 2020

Last week, AfterPay’s (ASX: APT) share reached our price target as it shot through the $100 barrier. The company announced a deal with WestPac (ASX: WBC) that outlined the collaboration between the two companies. Starting in the second quarter of 2021, AfterPay will be launching new financial products for its customers, including savings accounts, using the WestPac’s Banking-as-a-Service (BaaS) platform.

This BaaS platform, which is Cloud-based, allows WestPac to partner with FinTech’s, like AfterPay, to rapidly bring new and existing financial services to market. In this case, the platform allows AfterPay to offer its customers savings accounts without having a banking license. That part is taken care of by WestPac, which is a major advantage for AfterPay as it doesn’t have the compliance and balance sheet obligations that a banking license brings. The kicker for WestPac is getting access to a new, large, potential client base, mostly the Millenial cohort, that has proven to be elusive to traditional banks.

We believe these types of collaborations open up vast new growth opportunities for Buy Now, Pay Later (BNPL) companies, not just in Australia, but globally. We see a brave new world where BNPL customers can use AfterPay not just to buy things in 4 installments, but can get a mortgage and open trading accounts with the company.

 

Want to become a better investor. Let us help you!

 

Get our 4 publications per week on ASX-listed

large, mid and small cap companies across all sectors

Model portfolios

Investor Webinars

 

Get access to all editions through a 30-day FREE TRIAL.

No credit card required!

GET A 30-DAY FREE TRIAL

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

Nuix

Nuix (ASX:NXL) has quadrupled in 12 months! But is more growth to come?

Nuix (ASX:NXL) has been one of the most controversial companies on the ASX since it listed, but has it turned…

ASX Biotechs

Here are 3 ASX biotechs with major milestones coming right up!

Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own…

buy the dip

When do you know it’s time to ‘buy the dip’? You could be catching a falling knife

‘Buy the dip’ – have you ever heard that term? It implies that when a company’s share price ‘dips’ or decreases,…